Based on the fact that there existed regulatory mechanisms between miR-6734-3p and ZEB2, and they had opposite effects in regulating cancer progression [15,16,21–23], our data evidenced that miR-6734-3p targeted ZEB2 to hinder the development of NSCLC, implying that targeting the miR-6734-3p/ZEB2 axis was a novel strategy to treat NSCLC. Here, ZEB2 is linked to cancer.